This is an evolutionary step forward. At MindWalk, we're redefining biologics research through advanced AI, powered by our LensAI™ platform at the core. Discover how we're bringing biology to the future: youtube.com/watch?v=--o0ELDF… 🇺🇸 #NASDAQ: $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗶𝘀 𝗶𝗻 𝗡𝗲𝘄 𝗬𝗼𝗿𝗸 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗛.𝗖. 𝗪𝗮𝗶𝗻𝘄𝗿𝗶𝗴𝗵𝘁 𝟮𝟴𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗚𝗹𝗼𝗯𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲, 𝗦𝗲𝗽𝘁. 𝟭𝟰-𝟭𝟲𝘁𝗵. Join us at the Lotte New York Palace Hotel as we meet with investors, partners, and industry leaders and share how ReefIQ™ is creating the biological data foundation for AI-enabled drug discovery. Today at 4:30 PM ET, MindWalk's President and CEO Jennifer Bath, PhD, takes the stage to highlight the latest advancements in ReefIQ™, including how it connects fragmented discovery data and adds the biological context that makes AI reasoning reliable across complex research environments. Dr. Bath will also discuss how MindWalk's commercial model is shifting toward multi-year, recurring platform relationships, and why value in AI-enabled discovery accrues to the data layer rather than to any individual model. 📍 Lotte New York Palace Hotel, New York City 📅 September 14–16, 2026 Register for the in-person event: hcwevents.com/annualconferen… @HCWCO #HCWConference #MindWalk #ReefIQ #DrugDiscovery #BioNativeAI #Biotech $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗢𝗯𝘁𝗮𝗶𝗻𝘀 𝗕𝗶𝗻𝗱𝗶𝗻𝗴 𝗖𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗨𝗦$𝟯𝟬 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗨𝗻𝘀𝗲𝗰𝘂𝗿𝗲𝗱 𝗖𝗿𝗲𝗱𝗶𝘁 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗙𝘂𝗻𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝘀 𝗮𝗻𝗱 𝗥𝗲𝗲𝗳𝗜𝗤™ 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 Fixed 7.00% rate. No financial maintenance covenants. No warrants or equity conversion features. No dilution to existing shareholders. "This facility funds our biologics programs and the commercial expansion of ReefIQ™ without issuing a single share. We were not prepared to raise capital of this size in equity at the current share price, and we did not have to. Sanabil took no warrants, no conversion feature, and no security over any asset we own, so the full benefit of executing our plan stays with the shareholders who own it today. ReefIQ launched commercially in June, and we are in active negotiations with multiple large pharmaceutical companies on enterprise deployments. This facility gives us the balance sheet to make that shift to recurring, compounding revenue on our own terms." Jennifer Bath, PhD, MindWalk President and CEO See full release: ir.mindwalkai.com/news/news-… #MindWalk #ReefIQ #Biologics $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗦𝗵𝗼𝘄𝗰𝗮𝘀𝗲𝘀 𝗥𝗲𝗲𝗳𝗜𝗤™ 𝗳𝗼𝗿 𝗔𝗜 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗮𝘁 @AMD 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗜 𝟮𝟬𝟮𝟲 Today, unveiled the first public demonstration of ReefIQ™, its biological context layer for AI drug discovery, running on AMD Instinct™ at AMD’s Advancing AI 2026 in San Francisco. MindWalk is featured in the AMD Instinct™ Demo Showcase, appearing in one of four custom demo vignettes, with an accompanying video interview distributed through AMD’s channels. See full release: ir.mindwalkai.com/news/news-… #AMD #ReefIQ #MindWalk #AMDInstinct

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗛𝗬𝗙𝗧) 𝗔𝗱𝗱𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝗥𝘂𝘀𝘀𝗲𝗹𝗹 𝟯𝟬𝟬𝟬𝗘 𝗜𝗻𝗱𝗲𝘅, 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 Announced that it has been added to the Russell 3000E Index, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. “Being added to the Russell 3000E Index is a meaningful visibility milestone in MindWalk’s evolution as a public company. It places us in front of a broader set of institutional investors and index-tracking funds that had no mechanism to consider MindWalk before. We see this as one more signal that the market is starting to price the infrastructure layer beneath biological AI, not just the AI models running on top of it. ” Jennifer Bath, Ph.D., Chief Executive Officer and President, MindWalk Holdings Corp. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-… $HYFT #MindWalk #RussellIndex #DrugDiscovery

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗛𝗬𝗙𝗧) 𝗙𝗶𝗹𝗲𝘀 𝗣𝗮𝘁𝗲𝗻𝘁 𝗳𝗼𝗿 𝗛𝗶𝗴𝗵-𝗗𝗶𝗺𝗲𝗻𝘀𝗶𝗼𝗻𝗮𝗹 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗗𝗮𝘁𝗮 𝗔𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 𝗣𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗔𝗜 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 The patent covers the multi-dimensional biological representation layer organized around MindWalk’s HYFT® pattern anchors — the model-agnostic context layer designed to support ReefIQ™, LensAI™, and customer-selected AI workflows as they retrieve, compare, and reason over connected, traceable biology in drug discovery. “As AI models become more broadly available, we believe lasting advantage in life sciences will come from the biological context those models can use. The differentiator is not a generic AI interface, but the structured biological representation that lets models and agentic workflows retrieve connected evidence, preserve provenance, and reuse knowledge across programs. This filing is intended to protect aspects of the architecture at the core of HYFT® Technology, where MindWalk believes lasting value in biological AI can compound.” — Jennifer Bath, Ph.D., Chief Executive Officer and President, MindWalk Holdings Corp. 𝗦𝗲𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-… $HYFT #ReefIQ #HYFT #MindWalk

𝗧𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝗔𝗪𝗦 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗶𝗻𝘃𝗶𝘁𝗲 𝘁𝗼 𝘁𝗵𝗲 𝗔𝗪𝗦 𝗔𝗜 𝗛𝗲𝗮𝗹𝘁𝗵 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗙𝗼𝗿𝘂𝗺: “Transforming Healthcare with Agentic AI, Today’s Health Data, Tomorrow’s Care: Enabling AI-Powered Research for Precision Therapy” in Zürich, where Arnout Van Hyfte from MindWalk was a panelist. The session got to the heart of a tension most in this space live with: health data is abundant, but getting it into a form that actually improves patient outcomes is still the hard part. That gap between data and actionable insight is where a lot of promising science stalls. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗮𝗻𝗲𝗹𝗶𝘀𝘁𝘀 Anders Nordell, Dr. Tal Tova Patalon, MD, LL.B, MBA, Timo Kanninen, and Georg Langs for a conversation worth having. @awscloud #AWS #PrecisionMedicine #HealthAI #AgenticAI #MindWalk

𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗝𝗼𝗻𝗲𝘀 𝗧𝗿𝗮𝗱𝗶𝗻𝗴 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝗲𝘀𝗶𝗱𝗲 𝗽𝗮𝗻𝗲𝗹 𝗮𝘁 𝗝𝗼𝗻𝗲𝘀 𝗔𝗜 𝗗𝗮𝘆 — "𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴 𝘁𝗼 𝗣𝗼𝘄𝗲𝗿 𝘁𝗵𝗲 𝗡𝗲𝘄 𝗘𝗿𝗮 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆." MindWalk CEO Jennifer Bath, Ph.D. joined AMD Senior Manager of Strategic Industries Antonio Nunes and Absci CFO and CBO Zach Jonasson for a wide-ranging conversation on where in AI drug discovery is today and where it is rapidly moving. 𝗧𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝘃𝗲𝗿𝗲𝗱: • Why the model layer is already commoditizing — and where differentiation is moving next • How high-performance compute is collapsing screening timelines from months to hours • What challenges AI models face in biology — and why a bigger model isn't always the fix • Why connected biological context in data is the scarcest — and most overlooked — resource in AI drug discovery Dr. Jennifer Bath, MindWalk CEO and President stated: "The model layer is already commoditizing — that's really the point. The key question is what data it runs on. That's where the differentiation moves next: to the context layer." Thank you also to Jones Research Senior Analysts Debanjana Chatterjee, PhD and Danya Ben-Hail for moderating the event. $HYFT $ABSI @jonestrading @AMD @abscibio #JonesTrading #MindWalk #HYFT #DrugDiscovery #AIDrugDiscovery #Absci #AMD #Biologics #LifeSciences

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗛𝗬𝗙𝗧) 𝗖𝗘𝗢 𝗗𝗿. 𝗝𝗲𝗻𝗻𝗶𝗳𝗲𝗿 𝗕𝗮𝘁𝗵 𝘁𝗼 𝗝𝗼𝗶𝗻 𝗔𝗯𝘀𝗰𝗶 (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗔𝗕𝗦𝗜) 𝗮𝗻𝗱 𝗮 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝗔𝗜 𝗖𝗼𝗺𝗽𝘂𝘁𝗲 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗿 𝗼𝗻 @𝗝𝗼𝗻𝗲𝘀 𝗔𝗜 𝗗𝗮𝘆 𝗣𝗮𝗻𝗲𝗹 𝗼𝗻 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗔𝗜 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discovery, including prolonged screening timelines and historically undruggable targets. 𝗝𝗼𝗻𝗲𝘀 𝗔𝗜 𝗗𝗮𝘆 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗣𝗮𝗻𝗲𝗹 𝗱𝗲𝘁𝗮𝗶𝗹𝘀: The event is open to institutional investors 𝗧𝗶𝘁𝗹𝗲: “Partnering to Power the New Era of Drug Discovery” 𝗣𝗮𝗻𝗲𝗹𝗶𝘀𝘁𝘀: MindWalk: Dr. Jennifer Bath, PhD, Chief Executive Officer and President Absci: Sean McClain, Founder and Chief Executive Officer Leading AI compute provider: Senior healthcare and life-science strategy leadership 𝗗𝗮𝘁𝗲: Monday, June 15, 2026 𝗧𝗶𝗺𝗲: 12:00 p.m. ET. 𝗥𝗦𝗩𝗣: Yuki Gonzalez: [email protected] 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: bit.ly/43smC2r @jonestrading @abscibio #Jonestrading #MindWalk #DrugDiscovery #HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗥𝗲𝗲𝗳𝗜𝗤™, 𝗮 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝘁𝗲𝘅𝘁 𝗟𝗮𝘆𝗲𝗿 𝗳𝗼𝗿 𝗔𝗜 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 Launched today: ReefIQ, a HYFT®-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs, omics, literature, evidence, provenance, and program history are transformed into a governed, queryable connected biological context for AI-enabled discovery. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: bit.ly/4g6euMs 𝗠𝗼𝗿𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻: mindwalkai.com/reefiq #MindWalk #ContextLayer #HYFT #DataOrchestration #TechBio #Biologics

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸'𝘀 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝗻𝗴𝘂𝗲 𝗗𝗮𝘁𝗮 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗮 𝗛𝗬𝗙𝗧® 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns Today's data document the platform delivering on its fundamental claim: HYFT® technology computationally prioritized the pan-serotype target before immunization, the experiment supported the binding-level prediction, and the experimentally supported target now anchors MindWalk's dengue pipeline IP position as a persistent asset within the company's Biointelligence Platform. "The central question for any AI drug discovery platform is whether its computational predictions correspond to real biology. HYFT® is built to identify functional patterns that are constrained by biophysical reality — patterns that evolution cannot easily escape because they are tied to structural and binding requirements. When animals immunized with immunogens built around that prediction produced antibodies that recognized antigens from all four dengue serotypes — and scrambled-sequence controls did not — the prediction was supported in a live immunological system. That is a closed prediction-to-result loop, and it is the first time we have documented one on this vaccine platform." said Dr. Jennifer Bath, PhD, Chief Executive Officer of MindWalk Holdings Corp. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-… @CDCgov @NIH @DARPA #MindWalk #Dengue #HYFT #Vaccine

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. 𝗗𝗲𝗽𝗹𝗼𝘆𝘀 𝗣𝗮𝗻𝗱𝗲𝗺𝗶𝗰 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Today, MindWalk announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The problem: RNA viruses have resisted broadly protective countermeasures not because the science is young, but because the discovery approach has a structural flaw. Across RNA virus countermeasure programs, three dynamics have consistently resisted conventional solutions: •The target keeps moving. •General-purpose AI inherits the flaw rather than solving it. •The cost of being wrong resets with every outbreak. The Pandemic Response Platform operates on the virus's instruction set: the biological patterns RNA viruses must maintain across all viable variants to attach to cells, replicate, and assemble. See full release: ir.mindwalkai.com/news/news-… #Vaccines #RNA #HantaVirus #Ebola #DrugDiscovery #MindWalk @NIH @CDCGlobal @CDCgov @DARPA

𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: MindWalk scientists have contributed antibody discovery work to more than twenty client-owned drug programs that have advanced into clinical trials, including ten currently active in Phase 1–3. Supported by more than 400 peer-reviewed publications and patents, this record reflects a scientific foundation with demonstrated experience across therapeutic areas and modalities. Today, MindWalk is building on that foundation by integrating AI, wet-lab discovery expertise, and HYFT Base™, its biological data orchestration layer, to advance the Company’s next generation of drug discovery. “Before AI was a hypothesis in life sciences, our scientists were generating the molecules that are now in clinical trials at our partners. That history is not a credential we display — it is a standard we hold ourselves to. When we bring a new capability into this organization, the question is always the same: can it meet the bar that wet-lab discovery set? HYFT® and LensAI™ were built by world-class scientists pursuing a singular focus: creating the most rigorous biological representation system ever developed.” — Dr. Jennifer Bath, PhD, Chief Executive Officer and President, MindWalk Holdings Corp. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗿𝗲𝗽𝗼𝗿𝘁: bit.ly/4wTI2TJ

Thanks to AMD for the MindWalk highlight showing what data can make possible in drug discovery when it is built to operate at scale. AMD Enterprise published a case study on HYFT Base running on AMD Instinct MI300X GPUs and EPYC CPUs. The results are significant: • 70% higher embedding throughput • 39% lower cost per query • Workloads accelerated from months to hours For MindWalk, those numbers matter because they improve the economics of running complex discovery workloads on top of a biological data foundation built for scale. HYFT Base is MindWalk’s biological data orchestration layer, built to connect customer program data to the broader biosphere through 660 million biological patterns and 25 billion relationships, while keeping customer data in the customer’s AWS account under their existing governance and compute commitments. When that data layer can operate faster and more efficiently, teams can explore more biology, test more ideas, and make better use of every program, dataset, and decision point. It is not just faster AI. It is the ability to make complex biological context usable at the scale drug discovery requires. Grateful to the AMD Enterprise team for the partnership and excited for what this work opens up for the future of drug discovery. See post: bit.ly/4dKvNRv #AMD #DrugDiscovery #AI #Pharma #LifeSciences

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗤𝟯 𝗙𝗶𝘀𝗰𝗮𝗹 𝟮𝟬𝟮𝟲 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗧𝗼𝗱𝗮𝘆 𝗮𝘁 𝟭𝟬:𝟯𝟬𝗔𝗠 𝗘𝗧 Please join us for a review of our overall results and key highlights, including: - Third Consecutive Quarter of Year-Over-Year Revenue Growth - First Annual Enterprise LensAI Platform Contract - Launch of B Cell Llama™ Nanobody Discovery Platform “This quarter, MindWalk reported its third consecutive year-over-year revenue increase and advanced three pipeline programs toward data readouts. US revenue doubled year over year, reflecting our deliberate strategic focus on North America — including the establishment of biologics services operations in the Boston and Cambridge area and ongoing commercial investment in that market. Recently, our largest enterprise AI client signed a one-year LensAI platform contract — the first of its kind for us. LensAI is actively being rolled out across our broader client base, and this is one type of contract we are scaling.” — Dr. Jennifer Bath, CEO & President, MindWalk Holdings Corp. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-… 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗖𝗮𝗹𝗹 MindWalk will host a live conference call on March 12, 2026, at 10:30 AM ET to discuss Q3 fiscal 2026 financial results and business developments. A replay is available following the conclusion of the call. 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗖𝗮𝗹𝗹 𝗮𝗻𝗱 𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 The live webcast will take place Thursday, March 12, 2026, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at: ir.mindwalkai.com/events-and… * 𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 * Event Title: MindWalk Holdings Corp. – Third Quarter Fiscal Year 2026 Financial Results Event Date: March 12, 2026, 10:30 AM (GMT-04:00) Eastern Time (US and Canada) Attendee URL: events.q4inc.com/attendee/48… 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗗𝗶𝗮𝗹-𝗶𝗻: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800) 715-9871 Conference ID: 3224490 $HYFT #MindWalk #DrugDiscovery

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗛𝗜𝗠𝗦𝗦 𝟮𝟬𝟮𝟲 (𝗠𝗮𝗿𝗰𝗵 𝟵–𝟭𝟮 | 𝗟𝗮𝘀 𝗩𝗲𝗴𝗮𝘀)? 𝗩𝗶𝘀𝗶𝘁 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗮𝘁 𝘁𝗵𝗲 𝗔𝗠𝗗 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟱𝟳𝟬. With @AMD, we’re demonstrating how high-performance infrastructure is powering a new era of drug discovery. See LensAI running at production scale on AMD EPYC™ and Instinct™ — enabling faster, more efficient therapeutic development. 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗖𝗧𝗢, 𝗗𝗶𝗿𝗸 𝗩𝗮𝗻 𝗛𝗬𝗙𝗧𝗘'𝘀 𝘁𝗮𝗹𝗸 "Transforming Drug Discovery: The Power of LensAI™ + AMD EPYC™ and Instinct™" 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: AMD Theater, Booth #2570 𝗗𝗮𝘁𝗲: Wednesday, March 11 4:30 PM PT 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗯𝗶𝗼-𝗻𝗮𝘁𝗶𝘃𝗲 𝗟𝗲𝗻𝘀𝗔𝗜. 𝗔𝗠𝗗 𝗵𝗶𝗴𝗵-𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗰𝗼𝗺𝗽𝘂𝘁𝗲. 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻-𝘀𝗰𝗮𝗹𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Schedule a meeting with our team at HIMSS bit.ly/47eFlR7 #HIMSS2026 #DrugDiscovery #HealthIT #DigitalHealth #MindWalk #AMD

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗶𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗶𝗻𝗴 𝗕 𝗖𝗲𝗹𝗹 𝗟𝗹𝗮𝗺𝗮™ — 𝗮 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝗿𝗮 𝗼𝗳 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀, 𝗺𝘂𝗹𝘁𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. VHH nanobodies solve a molecular engineering problem the industry has wrestled with for years. B Cell Llama extends our flagship B Cell Select® platform into llama-derived single-domain antibody biology, with LensAI™ available to guide each step: from target selection and immunogen design, to functional candidate triage, to in silico multispecific construct evaluation. Backed by peer-reviewed science. A study just published in ACS Biomacromolecules demonstrated modular VHH potency, cross-variant activity against targets that defeated approved therapies, and a newly described immune-priming mechanism. "What sets B Cell Llama apart is the ability to layer LensAI across the entire discovery process — triaging candidates by predicted function, and evaluating multispecific constructs in silico before a single molecule is built in the lab." — Dr. Jennifer Bath, CEO, MindWalk Holdings Corp. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁: ir.mindwalkai.com/news/news-… $HYFT #Nanobody #Bispecific #CART #VHH #BioNativeAI #DrugDiscovery

🗞️ INDUSTRY NEWS UPDATE: AI is playing a growing role in healthcare and life sciences, as adoption trends continue to expand across the sector. Read: aimagazine.com/news/how-and-… 🇺🇸 #NASDAQ: $HYFT

Our LensAI™ platform, powered by our core HYFT® technology, captures and reasons over biological context to link sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system with the potential to transform drug discovery. Explore: ir.mindwalkai.com/overview/d… 🇺🇸 #NASDAQ: $HYFT